Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|17|2|139-153

ISSN： 1389-4501

Source： Current Drug Targets, Vol.17, Iss.2, 2016-02, pp. : 139-153

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Small Molecules Targeting Ataxia Telangiectasia and Rad3-Related (ATR) Kinase: An Emerging way to Enhance Existing Cancer Therapy

By  

Current Cancer Drug Targets, Vol. 16, Iss. 3, 2016-03 ,pp. : 200-208

Bentham Science Publishers

Access to resources Recommend Favorite

The Development of Ataxia Telangiectasia Mutated Kinase Inhibitors

By  

Mini Reviews in Medicinal Chemistry, Vol. 14, Iss. 10, 2014-08 ,pp. : 805-811

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias

By Banerji Lolita   Sattler Martin  

Expert Opinion on Therapeutic Targets, Vol. 8, Iss. 3, 2004-06 ,pp. : 221-239

Informa Healthcare

Access to resources Recommend Favorite

Targeting survivin in cancer therapy

By Pennati Marzia   Folini Marco   Zaffaroni Nadia  

Expert Opinion on Therapeutic Targets, Vol. 12, Iss. 4, 2008-04 ,pp. : 463-476

Informa Healthcare

Access to resources Recommend Favorite

Molecular Modeling of Sulfonylmorpholinopyrimidines as the Ataxia Telangiectasis Mutated and RAD3-related (ATR) Protein Kinase Inhibitors by Computational Explorations

By  

Letters in Drug Design & Discovery, Vol. 12, Iss. 8, 2015-10 ,pp. : 661-672

Bentham Science Publishers

Access to resources Recommend Favorite